STOCK TITAN

Aytu BioPharma tender offer has not yet started

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SC 14D9

Rhea-AI Filing Summary

Aytu BioPharma, Inc. (AYTU) disclosed preliminary communications about a planned tender offer for all of its outstanding common stock. RoseApollo Merger Sub, Inc., a wholly owned subsidiary of Rosemont Pharmaceuticals Holdings, Inc., plans to make the offer under a merger agreement dated November 16, 2026. The tender offer has not yet commenced. When it begins, Rosemont and RoseApollo intend to file tender-offer materials with the SEC, and Aytu says it will then file a solicitation/recommendation statement. The current communication is informational, not an offer to purchase or a recommendation. Identified uncertainties include the offer’s timing, how many stockholders tender shares, whether offer and merger conditions are satisfied or waived, and events that could terminate the merger agreement.

Common stock par value $0.001 per share Aytu BioPharma common stock
tender offer regulatory
"planned tender offer by RoseApollo Merger Sub, Inc."
A tender offer is a proposal made by a person or company to buy shares from existing shareholders at a set price, usually higher than the current market value, within a specific time frame. It matters to investors because it can lead to a change in ownership or control of a company, and shareholders must decide whether to sell their shares at the offered price.
Schedule TO regulatory
"Tender Offer Statement on Schedule TO"
A phrase indicating that a company plans or intends to hold an event, publish information, or take an action at a specified future time, but that the timing is not guaranteed and may change. For investors it signals an expected milestone—like an earnings call, product launch, or filing—so think of it as a calendar note rather than a firm promise; timing shifts can affect trading, expectations, and planning.
forward-looking statements regulatory
"This filing includes forward-looking statements"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Has the tender offer for Aytu BioPharma (AYTU) started?

No; the tender offer has not yet commenced. RoseApollo Merger Sub and its parent, Rosemont Pharmaceuticals Holdings, intend to file the tender-offer materials when it begins.

Which documents will AYTU shareholders receive regarding the tender offer?

Shareholders will receive the offer to purchase, letter of transmittal and certain other tender-offer documents at no expense. Rosemont and RoseApollo intend to file these materials with the SEC when the offer commences.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

SCHEDULE 14D-9 

 

SOLICITATION/RECOMMENDATION STATEMENT

UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

AYTU BIOPHARMA, INC.

(Name of Subject Company)

 

 

AYTU BIOPHARMA, INC.

(Name of Person Filing Statement)

 

 

 

Common Stock, par value $0.001 per share

(Title of Class of Securities)

 

34962G208

(CUSIP Number of Class of Securities)

 

Ryan J. Selhorn

Chief Financial Officer, Corporate Secretary and Treasurer

Aytu BioPharma, Inc.

7900 East Union Avenue, Suite 920, Denver, Colorado 80237

(720) 437-6580 

(Name, address, and telephone numbers of person authorized to receive notices and communications

on behalf of the persons filing statement)

 

With copies to:

Anthony Epps

Dorsey & Whitney LLP

1400 Wewatta Street, Suite 400

Denver, Colorado 80202
(303) 352-1109

 

 

☒

 

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

 

 

 

This Schedule 14D-9 filing relates solely to preliminary communications made before the commencement of a planned tender offer by RoseApollo Merger Sub, Inc., a Delaware corporation (“Purchaser”) and a wholly owned subsidiary of Rosemont Pharmaceuticals Holdings, Inc., a Delaware corporation (“Parent”), for all of the outstanding shares of common stock of Aytu BioPharma, Inc., a Delaware corporation (the “Company”), pursuant to the Agreement and Plan of Merger, dated as of November 16, 2026 (the “Merger Agreement”), among Parent, Purchaser and the Company.

 

 

The information set forth under Items 1.01, 7.01 and 9.01 of the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) by the Company on November 16, 2026 (including all exhibits attached thereto) is incorporated herein by reference.

 

Additional Information and Where to Find It

 

The tender offer (the “Offer”) has not yet commenced. This document is for informational purposes only and is neither a recommendation, nor an offer to purchase nor a solicitation of an offer to sell any securities of the Company or any other entity, nor is it a substitute for any tender offer materials that Parent, Purchaser or the Company will file with the SEC. A solicitation and an offer to buy securities of the Company will be made only pursuant to an offer to purchase and related materials that Parent and Purchaser intend to file with the SEC. At the time the Offer is commenced, Parent and Purchaser will file a Tender Offer Statement on Schedule TO, including an offer to purchase, a letter of transmittal and related documents, with the SEC, and the Company thereafter will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the Offer. THE COMPANY’S SECURITYHOLDERS AND OTHER INVESTORS ARE URGED TO READ THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 REGARDING THE OFFER, AS THEY MAY BE AMENDED FROM TIME TO TIME, WHEN THEY BECOME AVAILABLE CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND SECURITYHOLDERS SHOULD BE READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE OFFER. The offer to purchase, the related letter of transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement on Schedule 14D-9, will be sent to all stockholders of the Company at no expense to them. The Tender Offer Statement on Schedule TO, the Solicitation/Recommendation Statement on Schedule 14D-9 and other related documents will be made available for free at the SEC’s website at www.sec.gov.

 

Forward-Looking Statements

 

This filing includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”). All statements other than statements of historical facts contained in this filing are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as “may,” “will,” “should,” “forecast,” “could,” “expect,” “suggest,” “believe,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. These statements are predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others, risks associated with: uncertainties as to the timing of the tender offer and the merger; uncertainties as to how many stockholders of the Company will tender their shares in the tender offer; the possibility that the conditions to the tender offer and the merger may not be satisfied or waived; the occurrence of any event that could give rise to the termination of the merger agreement; the effects of the transaction on relationships with employees, customers, suppliers and other business partners; potential stockholder litigation or regulatory action relating to the transaction; the Company’s overall financial and operational performance, potential adverse changes to the Company’s financial position or its business, the results of operations, strategy and plans, changes in capital markets and the ability of the Company to finance operations in the manner expected, risks relating to gaining market acceptance of its products, its partners performing their required activities, its anticipated future cash position, regulatory and compliance challenges and future events under current and potential future collaborations. Readers should refer to the risks described in “Risk Factors” in Part I, Item 1A of the Company’s most recent Annual Report on Form 10-K and in the other reports and documents it files with the United States Securities and Exchange Commission, as well as the tender offer documents to be filed by Rosemont and the Schedule 14D-9 to be filed by the Company.

 

 

Keep reading